Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.89 CAD
Change Today -0.02 / -1.05%
Volume 824.6K
PLI On Other Exchanges
Symbol
Exchange
OTC US
Toronto
Frankfurt
As of 4:00 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PLI) Snapshot

Open
C$1.92
Previous Close
C$1.91
Day High
C$1.95
Day Low
C$1.88
52 Week High
03/19/15 - C$2.87
52 Week Low
10/8/14 - C$1.40
Market Cap
1.1B
Average Volume 10 Days
3.0M
EPS TTM
C$-0.09
Shares Outstanding
580.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PLI)

Related News

No related news articles were found.

prometic life sciences inc (PLI) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PLI) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bio separations, plasma-derived therapeutics, and small-molecule drugs. The company offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment is also developing PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402 for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

197 Employees
Last Reported Date: 03/31/15
Founded in 1992

prometic life sciences inc (PLI) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$489.1K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$404.7K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
Chief Medical Officer, Independent Director a...
Total Annual Compensation: C$267.6K
General Counsel and Corporate Secretary
Total Annual Compensation: C$229.2K
Compensation as of Fiscal Year 2014.

prometic life sciences inc (PLI) Key Developments

ProMetic Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

ProMetic reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss attributable to owners of the parent of CAD 12.28 million, or CAD 0.02 per diluted share, compared to net earnings attributable to owners of the parent of CAD 23.96 million, or CAD 0.04 per diluted share, for the same quarter ended June 30, 2014. For the six months, the company reported net loss attributable to owners of the parent of CAD 31.06 million, or CAD 0.06 per share, compared to net earnings attributable to owners of the parent of CAD 16 million, or CAD 0.03 per share, for the same period ended June 30, 2014. Revenues were CAD 4.81 million, compared to CAD 10.15 million for the same period ended June 30, 2014.

ProMetic Life Sciences Inc. Announces Pbi 4050's Positive Safety Review Triggers Expansion of Phase II Clinical Trial in Metabolic Syndrome Patients

ProMetic Life Sciences Inc. reported that its PBI-4050 has been confirmed to be safe and well tolerated in the first 12 metabolic syndrome with associated type 2 diabetes patients, following review of the safety data by the Data Safety Monitoring Board. ProMetic is now proceeding with the enrollment of an additional 24 patients, as planned in the study protocol design. Since the beginning of the metabolic syndrome Phase II clinical trial, the first 12 patients have received on average the equivalent of more than 2 months of dosing per patient. PBI-4050 has now therefore exceeded more than 24 months of patients/product exposure and the Corporation anticipates having partial read out on biomarkers available before the end of this year. Metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes. It consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL (good) cholesterol, elevated blood pressure, and elevated blood glucose.

ProMetic Reports Earnings Results for the Second Quarter and Year-To-Date of 2015; Provides Revenues Guidance for the Second Half of 2015

ProMetic reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported that its revenues were $2.9 million compared to $4.4 million in the same quarter of 2014. Net loss was $14.8 million compared to net earnings of $23.4 million for the quarter ended June 30, 2014. The increase in the net loss is mainly due to the fact that in the second quarter 2014, the corporation had recognized an aggregate gain of $32.3 million in relation to the Nantpro business combination whereas this transaction did not impact in the second quarter 2015. Loss was $13.5 million, reflecting the lower revenues, higher R&D costs and one-off debt reorganization charges. That loss computes to a net loss per share of $0.02 for the quarter on both a basic and diluted basis. For the year to date adjusted EBITDA shows a loss of $11.5 million in second quarter of 2015 versus a loss of $8.5 million for 2014. The company provided revenues guidance for the second half of 2015. For the second half of 2015, the revenues are expected to exceed $20 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLI:CN C$1.89 CAD -0.02

PLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLI.
View Industry Companies
 

Industry Analysis

PLI

Industry Average

Valuation PLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.9x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 52.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.